Prospective and Retrospective Study Evaluating Epidemiological, Clinical, Molecular and Therapeutic Data of Prolymphocytic Leukemia T. A FILO Study.

What this Trial Is About

Prolymphocytic leukemia T is a rare and aggressive blood cancer affecting mainly elderly patients. It accounts for about 2% of mature lymphoid leukemias and 20% of prolymphocytic leukemias. This disease involves changes in chromosome 14 that affect T cell receptor genes, causing overexpression of the TCL1 gene. The molecular pathway IL2RG-JAK1-JAK3-STAT5B is often activated, contributing to the disease. Because standard chemotherapy often works poorly, treatments like alemtuzumab, an anti-CD52 antibody, have improved outcomes, but responses are usually temporary. Patients who respond may be considered for stem cell transplantation if eligible. New, better-tolerated therapies targeting survival pathways are being studied to improve management. This observational study collects and examines clinical, molecular, and therapeutic information from patients with prolymphocytic leukemia T. It involves both retrospective and prospective data analysis without testing new drugs or treatments. The study focuses on understanding the disease characteristics, treatment responses, and survival outcomes. Researchers aim to better characterize the disease and identify factors that influence treatment results and long-term survival. Participants will have their clinical and biological data collected and analyzed over about three years, including blood and bone marrow flow cytometry, tumor cell karyotyping, and molecular studies at diagnosis and relapse. The study tracks disease progression and response to treatments. No specific treatments are given as part of this study. Participants contribute data and samples to help improve knowledge and future care for this rare leukemia.

Observatory of Prolymphocytic Leukemia T